Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials      
clinical improvementclinical worseningdeathsPCR-negative conversion
Immunosuppressants drugs24 1.17 [1.00; 1.38], 5 RCTs, I2=0%
low degree of certainty
0.78 [0.53; 1.14], 4 RCTs, I2=36%
inconclusive result
1.08 [0.77; 1.52], 6 RCTs, I2=0%
inconclusive result
-
Immunostimulants drugs22 1.35 [0.83; 2.18], 3 RCTs, I2=50%
inconclusive result
0.63 [0.08; 4.94], 2 RCTs, I2=53%
inconclusive result
1.07 [0.84; 1.36], 7 RCTs, I2=9%
inconclusive result
6.33 [1.54; 26.00], 1 RCT, I2=0%
unassessable degree of certainty
corticosteroids14 1.16 [0.84; 1.60], 2 RCTs, I2=0%
inconclusive result
0.66 [0.43; 1.02], 1 RCT, I2=0%
inconclusive result
0.81 [0.65; 0.99], 7 RCTs, I2=59% demonstrated
low degree of certainty
-
anti-inflammatory therapies7 OBS 12.75 [1.61; 100.79], 1 study, I2=0%
unassessable degree of certainty
OBS 0.82 [0.19; 3.58], 3 studies, I2=76%
inconclusive result
OBS 0.86 [0.62; 1.21], 4 studies, I2=35%
inconclusive result
-
acalabrutinib2----
A EFFACER anticorps0----
Apilimod0----
imatinib0----
leflunomide0----
pirfenidone0----
Polyinosinic-Polycytidylic Acid0----
sargramostim0----
thymosin0----